| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CEACAM7 |
| Uniprot No | Q14002 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 36-242aa |
| 氨基酸序列 | TNIDVVPFNVAEGKEVLLVVHNESQNLYGYNWYKGERVHANYRIIGYVKN ISQENAPGPAHNGRETIYPNGTLLIQNVTHNDAGIYTLHVIKENLVNEEV TRQFYVFSEPPKPSITSNNFNPVENKDIVVLTCQPETQNTTYLWWVNNQS LLVSPRLLLSTDNRTLVLLSATKNDIGPYECEIQNPVGASRSDPVTLNVR YESVQAS |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CEACAM7重组蛋白的3篇文献及其摘要概括：
1. **"CEACAM7: A Novel Target for Colorectal Cancer Biomarker Development"**
*Authors: Smith A, et al.*
摘要：研究利用重组CEACAM7蛋白验证其在结直肠癌组织中的特异性表达，并探讨其作为血清诊断标志物的潜力，通过ELISA检测发现其在患者血清中显著升高。
2. **"Expression and Functional Analysis of Recombinant CEACAM7 in Epithelial Cells"**
*Authors: Lee J, et al.*
摘要：报道了在HEK293细胞中成功表达并纯化CEACAM7重组蛋白，功能实验表明其通过调控β-catenin信号通路抑制肿瘤细胞迁移，为癌症治疗提供新靶点。
3. **"Structural Characterization of CEACAM7 Glycosylation Using Recombinant Protein"**
*Authors: Müller C, et al.*
摘要：通过质谱分析重组CEACAM7的糖基化修饰模式，揭示其N-糖基化位点对细胞黏附和免疫逃逸功能的影响，为开发靶向糖基化药物提供依据。
(注：上述文献为模拟示例，实际引用需查询具体数据库。)
CEACAM7 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 7) is a member of the CEACAM family, a group of glycosylated cell surface proteins involved in intercellular recognition, signaling, and immune regulation. Primarily expressed in the gastrointestinal tract, CEACAM7 is notably associated with colorectal epithelial cells and has been implicated in both physiological processes and disease pathogenesis, particularly colorectal cancer. Its structure includes an N-terminal immunoglobulin (Ig)-like domain, followed by multiple Ig-like repeats, and a glycosylphosphatidylinositol (GPI) anchor for membrane attachment, enabling homophilic or heterophilic interactions with other CEACAMs or ligands.
Recombinant CEACAM7 protein is engineered to study its biological roles, leveraging expression systems like Escherichia coli or mammalian cells to produce soluble or membrane-bound variants. This recombinant form often retains key functional domains, enabling researchers to investigate its involvement in cell adhesion, apoptosis modulation, and immune evasion mechanisms. Studies suggest CEACAM7 may act as a tumor suppressor in early-stage colorectal cancer by regulating cell differentiation and proliferation, though its role remains context-dependent.
The protein’s potential as a diagnostic or therapeutic target has driven interest in recombinant production. Applications include in vitro binding assays, antibody development, and exploration of its interaction with pathogens (e.g., Helicobacter pylori) or immune receptors. Additionally, recombinant CEACAM7 aids in deciphering its glycosylation patterns, which influence ligand binding and cellular responses. Ongoing research focuses on its dual role in tumorigenesis and immune regulation, highlighting its relevance in both cancer biology and immunotherapy development.
×
